Pancreatic cancer - historical

The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. Is there a regimen missing from this list? See the main pancreatic cancer page for current regimens.
Last updated on 2024-07-23:3 regimens on this page
3 variants on this page
 
=Induction therapy for locally advanced disease, unresectable=
==FLEC==
FLEC: Fluorouracil, Leucovorin (Folinic acid), Epirubicin, Carboplatin
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Cantore et al. 2004	1997-2001 	Phase 3 (E-esc)	Gemcitabine	Seems to have longer OS (primary endpoint)Median OS: 7.9 vs 5.8 mo(HR not reported)
====Chemotherapy====
*Fluorouracil (5-FU) 1000 mg/m2 IA bolus once on day 1
*Leucovorin (Folinic acid) 100 mg/m2 IA bolus once on day 1
*Epirubicin (Ellence) 60 mg/m2 IA bolus once on day 1
*Carboplatin (Paraplatin) 300 mg/m2 IA bolus once on day 1
21-day cycle for 3 cycles
===References===
#Cantore M, Fiorentini G, Luppi G, Rosati G, Caudana R, Piazza E, Comella G, Ceravolo C, Miserocchi L, Mambrini A, Del Freo A, Zamagni D, Rabbi C, Marangolo M. Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology. J Chemother. 2004 Dec;16(6):589-94. link to original article dosing details in abstract have been reviewed by our editors EuroPMC
=Metastatic disease, first-line=
==PEFG==
PEFG: Platinol (Cisplatin), Epirubicin, Fluorouracil, Gemcitabine
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Reni et al. 2005	2000-2003 	Phase 3 (E-esc)	Gemcitabine	Higher PFS4 (primary endpoint)PFS4: 60% vs 28%(HR 0.46, 95% CI 0.26-0.79)
====Chemotherapy====
*Cisplatin (Platinol) 40 mg/m2 IV once on day 1
*Epirubicin (Ellence) 40 mg/m2 IV once on day 1
*Fluorouracil (5-FU) 200 mg/m2/day IV continuous infusion over 28 days, started on day 1 (total dose per cycle: 5600 mg/m2)
*Gemcitabine (Gemzar) 600 mg/m2 IV over 60 minutes once per day on days 1 & 8
28-day cycles
===References===
#Reni M, Cordio S, Milandri C, Passoni P, Bonetto E, Oliani C, Luppi G, Nicoletti R, Galli L, Bordonaro R, Passardi A, Zerbi A, Balzano G, Aldrighetti L, Staudacher C, Villa E, Di Carlo V. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol. 2005 Jun;6(6):369-76. link to original article dosing details in abstract have been reviewed by our editors EuroPMC
=Metastatic disease, all lines of therapy=
==SMF==
SMF: Streptozotocin, Mitomycin, 5-Fluorouracil
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator	Comparative Efficacy
Kelsen et al. 1991	1987-1989 	Phase 3 (C)	CAC 	Longer OS
====Chemotherapy====
*Streptozocin (Zanosar) 1000 mg/m2 IV once per day on days 1, 8, 29, 36
*Mitomycin (Mutamycin) 10 mg/m2 IV once on day 1
*Fluorouracil (5-FU) 600 mg/m2 IV once per day on days 1, 8, 29, 36
8-week cycles
===References===
#Kelsen D, Hudis C, Niedzwiecki D, Dougherty J, Casper E, Botet J, Vinciguerra V, Rosenbluth R. A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma. Cancer. 1991 Sep 1;68(5):965-9. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
Category:Pancreatic cancer regimens
Category:Disease-specific pages
Category:Gastrointestinal cancers
Category:Historical regimens